# Chicago Growth Partners

> Chicago Growth Partners is a VC fund backing Health Care and Analytics. See 16 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Chicago, United States
- Total investments: 16
- Last investment: Jun 2018
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/chicago-growth-partners
- X (Twitter): http://twitter.com/ChicagoGrowth
- Website: http://www.cgp.com

Chicago Growth Partners (CGP) is a Midwest US based private equity firm that provides expansion and buyout capital to middle-market companies. For expansion capital financings, CGP will invest $5 to $25 million of equity in companies generating at least $10 million in revenue and growing at least 15% per year. For buyout situations, CGP invests $10to $40 million in businesses with at least $20 million in revenue. Broad sectors of interest include business services, consumer services, healthcare products/services, and industrial. CGP was formed in 2004 and is based in Chicago, Illinois.

## Contacts

5 contacts available for Chicago Growth Partners. Shizune tracks 10 team members at Chicago Growth Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/chicago-growth-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 25% |
| Analytics | 2 | 13% |
| Advertising | 2 | 13% |
| Biotechnology | 2 | 13% |
| Medical Device | 2 | 13% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 19% |
| Funding Round | 2 | 13% |
| Series A | 1 | 6% |
| Series D | 1 | 6% |
| Series E | 1 | 6% |

9 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Adam Kimura | Associate | 0 | — |
| Arda Minocherhomjee | Managing Partner | 18 | — |
| Devin Mathews | Partner | 1 | — |
| Jeff Farrero | Principal | 0 | — |
| Sean Barrette | Vice President | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EndoGastric Solutions | EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington. | $40.6M | Series I | Jun 19, 2018 |  |
| EndoGastric Solutions | EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington. | $50M |  | Dec 01, 2015 |  |
| Verifone | 2Checkout is the leading all-in-one monetization platform for global businesses. It was built to help clients drive sales growth across channels and increase market share by simplifying the complexities of modern commerce like global payments, subscription billing, merchandising, taxes, compliance and risk, so they stay focused on innovating theirproducts and delivering exceptional customer experiences. | $60M | Series A | Jul 16, 2014 |  |
| Medical Scribe Systems | ScribeAmerica was established in 2003, while the concept of medical scribe utilization in the industry has been anecdotally reported since the 1970's, ScribeAmerica transformed this cottage operation into a national industry. In 2006, we were the first company to demonstrate that the synergy of the Scribe/MD/EMR model could overcomeproductivity losses experienced by unassisted physicians using EMR. In 2008, we were the first scribe company providing services on both coasts and the only scribe company present at ACEP, AAOS, and SHM. We credit our success to our generous profit-sharing business model whereby the actual Project Leaders who manage our client's programs are rewarded. By enfranchising our employee base, we ensure limited attrition among management and attract the best talent in the industry to run your program. |  | Debt Financing | Jul 01, 2014 |  |
| EndoGastric Solutions | EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington. | $30M | Series G | May 06, 2014 |  |
| EndoGastric Solutions | EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington. | $13M |  | Jun 21, 2012 |  |
| EndoGastric Solutions | EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington. | $2.1M |  | Apr 01, 2012 |  |
| EndoGastric Solutions | EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington. | $30M | Series F | Aug 30, 2010 |  |
| Zogenix | At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatmentof central nervous system disorders and pain. Our lead product candidate, sumatriptan DosePro™, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain. | $15M |  | Jul 13, 2010 |  |
| Zogenix | At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatmentof central nervous system disorders and pain. Our lead product candidate, sumatriptan DosePro™, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain. | $35M | Series B | Dec 15, 2009 |  |

10 of 16 investments shown.

## Co-investors
- [Advanced Technology Ventures](https://shizune.co/investors/profile/advanced-technology-ventures) — VC Fund, 7 deals together
- [Foundation Medical Partners](https://shizune.co/investors/profile/foundation-medical-partners) — VC Fund, 6 deals together
- [DeNovo Ventures](https://shizune.co/investors/profile/denovo-ventures) — VC Fund, 5 deals together
- [Radius Ventures](https://shizune.co/investors/profile/radius-ventures) — VC Fund, 5 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 2 deals together
- [CRV](https://shizune.co/investors/profile/crvvc) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Chicago Growth Partners invest in?

Chicago Growth Partners invests primarily in Health Care, Analytics and Advertising startups, most often at Series B and Funding Round stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Chicago Growth Partners?

Public channels for Chicago Growth Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Chicago Growth Partners?

The team at Chicago Growth Partners includes Adam Kimura (Associate), Arda Minocherhomjee (Managing Partner) and Devin Mathews (Partner), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co